# US 2024/0002951 A1 · Methods for classification of liver disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002951 A1
- Document ID: US20240002951A1
- Status: Published application
- Kind: A1
- Application number: 18/254,433
- Filed: 2021-11-30
- Published: 2024-01-04
- Earliest claimed: 2020-12-01
- Assignees: Tensor Biosciences, Inc.
- Applicants: Tensor Biosciences, Inc
- Inventors: Leila Celeste SIDOW; Arend SIDOW; Anton VALOUEV; Aijaz AHMED
- Web page: https://patentgrep.com/patent/US20240002951A1

## CPC

- A61P 35/00: Antineoplastic agents
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 1/6827: for detection of mutation or polymorphism
- C12Q 1/686: Polymerase chain reaction [PCR]
- C12Q 1/6869: Methods for sequencing
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G06N 3/02: Neural networks
- G16B 5/20: Probabilistic models
- G16B 20/20: Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
- G16B 40/20: Supervised data analysis
- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/154: Methylation markers
- G01N 2800/08: Hepato-biliairy disorders other than hepatitis
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G06N: COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A method of classifying a liver disease by analyzing a DNA sample, wherein the DNA sample comprises cfDNA and/or blood cell DNA, the method comprising: obtaining the DNA sample; determining CpG methylation status at CpG sites of DNA molecules of the DNA sample; identifying a methylation pattern based on the CpG methylation status of the DNA molecules; assigning to the sample a liver disease classification based on the methylation pattern.

## Claims

### Claim 1

A method of classifying a liver disease by analyzing a DNA sample, wherein the DNA sample comprises cfDNA and/or blood cell DNA, the method comprising:
(a) obtaining the DNA sample;
(b) determining CpG methylation status at CpG sites of DNA molecules of the DNA sample;
(c) identifying a methylation pattern based on the CpG methylation status of the DNA molecules;
(d) assigning to the sample a liver disease classification based on the methylation pattern.

### Claim 2 (depends on 1)

The method of any of claims 1 and following wherein the DNA sample comprises cfDNA fragments.

### Claim 3 (depends on 1)

The method of any of claims 1 and following wherein the DNA sample comprises DNA fragments from blood cells.

### Claim 4 (depends on 2, 3)

The method of any of claim 2 or 3 wherein smaller-sized fragments are obtained from the original fragments using shearing or restriction digestion.

### Claim 5 (depends on 2, 3)

The method of any of claim 2 or 3 wherein the fragments are enriched by hybridization to a set of probes of a targeted panel.

### Claim 6 (depends on 2, 3)

The method of any of claim 2 or 3 wherein the fragments are enriched using FOR with a panel of primers.

### Claim 7 (depends on 1)

The method of any of claims 1 and following wherein the methylation pattern is used to calculate a methylation level indicating a probability that the sample belongs to a particular liver disease classification.

### Claim 8 (depends on 1)

The method of any of claims 1 and following wherein step 1(d) comprises comparing the methylation level to a cut-off to classify the liver disease.

### Claim 9 (depends on 1)

The method of any of claims 1 and following further comprising reporting a probability of a stage of liver disease with a score derived from the methylation level of the DNA sample.

### Claim 10 (depends on 1)

The method of any of claims 1 and following wherein step 1(d) comprises classifying the sample as having a probability of:
(a) no liver disease;
(b) non-alcoholic fatty liver disease;
(c) non-alcoholic steatohepatitis;
(d) liver cirrhosis; and/or
(e) liver carcinoma.

### Claim 11 (depends on 1)

The method of any of claims 1 and following wherein step 1(d) comprises classifying the sample for a stage of fibrosis.

### Claim 12 (depends on 11)

The method of claim 11 wherein classifying the sample for a stage of fibrosis comprises classifying the sample as having a probability of:
(a) no fibrosis;
(b) portal fibrosis without septa;
(c) portal fibrosis with few septa;
(d) periportal fibrosis;
(e) bridging fibrosis; and/or
(f) cirrhosis.

### Claim 13 (depends on 11)

The method of claim 11 wherein classifying the sample for a stage of fibrosis comprises classifying the sample as having a probability of:
(a) F0 fibrosis;
(b) F1 fibrosis;
(c) F2 fibrosis;
(d) F3 fibrosis;
(e) F4 fibrosis; and/or
(f) cirrhosis.

### Claim 14 (depends on 1)

The method of any of claims 1 and following wherein step 1(d) comprises classifying the sample for a hepatitis.

### Claim 15 (depends on 14)

The method of claim 14 wherein classifying the sample for a hepatitis comprises classifying the sample as having a probability of:
(a) no hepatitis;
(b) non-specific reactive hepatitis;
(c) granulomatous hepatitis;
(d) chronic active hepatitis;
(e) acute hepatitis;
(f) autoimmune hepatitis;
(g) alcoholic hepatitis; and/or
(h) nonalcoholic hepatitis.

### Claim 16 (depends on 1)

The method of any of claims 1 and following wherein step 1(d) comprises classifying the sample for a grade of liver inflammation.

### Claim 17 (depends on 16)

The method of claim 16 wherein classifying the sample for a grade of liver inflammation comprises classifying the sample as having a probability of:
(a) no inflammation;
(b) mild inflammation;
(c) moderate inflammation; and/or
(d) marked or severe inflammation.

### Claim 18 (depends on 1)

The method of any of claims 1 and following wherein step 1(d) comprises classifying the sample for a grade of liver necrosis.

### Claim 19 (depends on 18)

The method of claim 18 wherein classifying the sample for a grade of liver necrosis comprises classifying the sample as having a probability of:
(a) no necrosis;
(b) mild necrosis;
(c) moderate necrosis; and/or
(d) marked or severe necrosis.

### Claim 20 (depends on 1)

The method of any of claims 1 and following wherein step 1(d) comprises classifying the sample for a level of fat in the liver.

### Claim 21 (depends on 7)

The method of any of claims 7 and following wherein the methylation level is established by identifying coefficients for one or more CpG features by fitting a model based on methylation patterns in the DNA sample.

### Claim 22 (depends on 21)

The method of claim 21 wherein the model is fitted using data from samples from a training set.

### Claim 23 (depends on 22)

The method of claim 22 wherein the samples comprise DNA samples from:
(a) subjects with liver disease; and
(b) subjects without liver disease.

### Claim 24 (depends on 21)

The method of claim 21 wherein the one or more CpG features comprise a single CpG site.

### Claim 25 (depends on 21)

The method of claim 21 wherein the one or more CpG features comprise a set of CpG sites located on the same DNA fragment.

### Claim 26 (depends on 21)

The method of claim 21 wherein the one or more CpG features are derived using mutual information analysis.

### Claim 27 (depends on 21)

The method of claim 21 wherein the one or more CpG features are derived using L1 logistic regression.

### Claim 28 (depends on 21)

The method of claim 21 wherein the model comprises a logistic regression model.

### Claim 29 (depends on 21)

The method of claim 21 wherein the model comprises a logistic regression model with L2 penalty.

### Claim 30 (depends on 21)

The method of claim 21 wherein the model comprises a logistic regression model with L1 penalty.

### Claim 31 (depends on 21)

The method of claim 21 wherein the model comprises a random forest.

### Claim 32 (depends on 21)

The method of claim 21 wherein the model comprises a neural network.

### Claim 33 (depends on 21)

The method of claim 21 wherein the model comprises a support vector machine.

### Claim 34 (depends on 21)

The method of claim 21 wherein the model comprises a gradient boosting algorithm.

### Claim 35 (depends on 21)

The method of claim 21 wherein the model comprises a naive Bayes.

### Claim 36 (depends on 1)

The method of any of claims 1 and following wherein the cfDNA sample comprises genomic regions that are enriched by a targeted panel, wherein the panel is established by a method comprising:
(a) selecting a set of genomic regions based on cfDNA samples from subjects with and without liver disease using:
(i) mutual information;
(ii) variation based on a cutoff requirement; or
(iii) L1 logistic regression; and
(b) selecting a set of genomic regions based on liver tissue DNA samples from subjects with and without liver disease using:
(i) mutual information;
(ii) variation based on a cutoff requirement; or
(iii) L1 logistic regression; and
(c) selecting a set of genomic regions based on samples of DNA obtained from purified hepatocytes, adipocytes, fibroblasts, and/or immune cells using:
(i) mutual information;
(ii) variation based on a cutoff requirement; or
(iii) L1 logistic regression.

### Claim 37 (depends on 1)

The method of any of claims 1 and following wherein the DNA sample comprises blood cell DNA.

### Claim 38 (depends on 37)

The method of claim 37 wherein the DNA from the blood cell sample comprises genomic regions that are enriched by a targeted panel, which is established by a method comprising:
(a) selecting a set of genomic regions based on blood cell samples from a training set from subjects with and without liver disease using:
(i) mutual information;
(ii) variation based on a cutoff requirement; or
(iii) L1 logistic regression; and
(b) selecting a set of genomic regions based on samples from purified T cells, B cells, granulocytes and/or neutrophils using:
(i) mutual information;
(ii) variation based on a cutoff requirement; or
(iii) L1 logistic regression.

### Claim 39 (depends on 1)

The method of any of claims 1 and following wherein step 1(b) comprises determining the presence of 5 mC or 5 hmC modifications at individual sites of the DNA molecules using a method comprising methylation-aware sequencing.

### Claim 40 (depends on 1)

The method of any of claims 1 and following wherein step 1(b) comprises determining average levels of 5 mC or 5 hmC across individual genomic CpG sites of the DNA molecules using a method comprising a methylation-aware DNA array method.

### Claim 41 (depends on 1)

The method of any of claims 1 and following wherein step 1(b) comprises determining average levels of 5 mC or 5 hmC at a selected set of genomic CpG sites of the DNA molecules using a method comprising PCR, qPCR or digital PCR.

### Claim 42 (depends on 1)

The method of any of claims 1 and following wherein step 1(b) comprises converting the DNA molecules using sodium bisulfite treatment.

### Claim 43 (depends on 1)

The method of any of claims 1 and following wherein step 1(b) comprises converting the DNA molecules by TET2-assisted DNA oxidation and APOBEC-assisted cytosine deamination.

### Claim 44 (depends on 1)

The method of any of claims 1 and following wherein step 1(b) comprises binding the DNA molecules to a DNA array and enriching the sample using probes from the targeted panel.

### Claim 45 (depends on 1)

The method of any of claims 1 and following wherein step 1(b) comprises performing methylation-aware sequencing of the DNA molecules.

### Claim 46 (depends on 1)

The method of any of claims 1 and following wherein step 1(b) comprises detecting methylation levels of CpG sites of the DNA molecules using a DNA array.

### Claim 47 (depends on 1)

The method of any of claims 1 and following wherein step 1(b) comprises detecting methylation levels of CpG sites of the DNA molecules using PCR, qPCR or digital PCR.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

A method of treating a subject comprising:
(a) testing the subject according to the method of any of claims 1 to 47; and
(b) administering to the subject a therapy selected to treat a disease corresponding to the disease classification.
